elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Complete response
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Complete response
RIS
0.005
(Research Intensity Score)
Papers
956
Top papers
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2022 · 2627 citations
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 · 1084 citations
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2023 · 479 citations
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
2024 · 222 citations
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2021 · 935 citations
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
2022 · 274 citations
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
2023 · 177 citations
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023 · 140 citations
Newest papers
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2026 · 58 citations
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · 12 citations
Correlation of tumor maximum standardized uptake value from 18F-BPA PET and boron neutron capture therapy tumor dose with treatment outcomes in head and neck cancer: a retrospective analysis
2026 · 2 citations
Abstract PD7-10: Neo-n (neon): three-year event-free survival and ultrasensitive ctdna dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin/paclitaxel and nivolumab
2026 · 3 citations
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette–Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
2025 · 38 citations
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
2025 · 41 citations
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial
2025 · 35 citations
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
2025 · 38 citations
Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms
2025 · 29 citations
Browse all papers →
Complete response's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Complete response's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link